OKYO Pharma (NASDAQ:OKYO) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of OKYO Pharma (NASDAQ:OKYO) in a research note published on Monday morning,Benzinga reports. They currently have a $7.00 price objective on the stock.

OKYO Pharma Stock Down 1.8 %

Shares of NASDAQ OKYO opened at $1.10 on Monday. The business has a 50-day moving average of $1.08 and a two-hundred day moving average of $1.07. OKYO Pharma has a 1 year low of $0.81 and a 1 year high of $1.90.

OKYO Pharma Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.